
Core Viewpoint - SciSparc Ltd. is advancing its clinical trial for SCI-210, a treatment for autism spectrum disorder (ASD), with the first five patients enrolled in Israel, aiming for commercialization in the Israeli market first [1][3]. Group 1: Clinical Trial Details - The ongoing clinical trial is a double-blind, randomized, and placebo-controlled study involving 60 subjects aged 5 to 18 over a 20-week period [2]. - The trial will assess the efficacy of SCI-210, which combines cannabidiol (CBD) and CannAmide™, against standard CBD monotherapy in managing ASD symptoms [2][3]. - Primary efficacy metrics include the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, Clinical Global Impressions-Improvement (CGI-I) by clinicians, and effective therapeutic dose [3]. Group 2: Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals, with other drug development programs targeting Tourette Syndrome, Alzheimer's disease, and pain management [6]. - The company is led by an experienced team and aims to enhance its portfolio of technologies and assets based on cannabinoids [6]. Group 3: ASD Context - Autism spectrum disorder (ASD) affects social interaction and communication, with a wide range of symptoms and severity [5]. - Treatments and services can improve symptoms and daily functioning for individuals diagnosed with ASD [4].